Presage Biosciences, Inc.

Seattle, WA 98109

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $3.71MM
Active Awards 1 valued at $1MM
First Award Date 07/01/10
Most Recent Award Date 09/01/17

Key Personnel

Last Name Name Awards Contact
Olson James M Olson 5
Klinghoffer Richard Klinghoffer 4

7 Awards Won

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: RFA-CA-15-010
Budget: 09/01/17 - 08/31/18

? DESCRIPTION (provided by applicant): Improvements in cancer diagnostics and therapeutics have positively impacted outcomes for oncology patients within select clinical niches. However, significant therapeutic uncertainty awaits the majority of today's oncology patients who present in the clinic with cancer that will relapse after exhibiting...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-15-010
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): Improvements in cancer diagnostics and therapeutics have positively impacted outcomes for oncology patients within select clinical niches. However, significant therapeutic uncertainty awaits the majority of today's oncology patients who present in the clinic with cancer that will relapse after exhibitin...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): With few exceptions, extensive characterization of signal pathway alterations in cancer, and advances in our capacity to identify potent modulators of distinct molecular targets, has not translated into breakthrough drugs. In a recent New York Times article (Nov. 14, 2009), Mervyn Turner, Chief Strategy Offic...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): With few exceptions, extensive characterization of signal pathway alterations in cancer, and advances in our capacity to identify potent modulators of distinct molecular targets, has not translated into breakthrough drugs. In a recent New York Times article (Nov. 14, 2009), Mervyn Turner, Chief Strategy Offic...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-09-081
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific information about drug resistance and sensitivity...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-09-081
Budget: 05/01/11 - 04/30/12

DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific information about drug resistance and sensitivity...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-09-081
Budget: 07/01/10 - 12/31/10

DESCRIPTION (provided by applicant): Over 90% of cancer patients that enroll in Phase I or II clinical trials experience no benefit from the experimental therapies, yet are exposed to drug toxicity and other challenges related to treatment. For over 50 years, physicians have used patient-specific information about drug resistance and sensitivity...